Mucosolvan (Ambroxol Hydrochloride)

Ambroxol Hydrochloride, the active ingredient in Mucosolvan, is a mucolytic presented as an oral formulation for oral use. It reduces the viscosity of respiratory mucus, aiding clearance in patients with acute or chronic bronchial conditions.

GNH USA supplies Mucosolvan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for bulk and unit‑dose shipments across multiple regions. Customers benefit from dedicated regulatory support and transparent pricing.

Mucosolvan, a mucolytic agent, is used to manage conditions characterized by excessive or thickened respiratory secretions.

- Acute bronchitis: helps reduce mucus viscosity and facilitates expectoration, improving cough efficiency. - Chronic bronchitis: aids in clearing sputum, decreasing cough frequency and improving breathing comfort. - Chronic obstructive pulmonary disease (COPD): supports mucus clearance, contributing to better airway patency during exacerbations. - Respiratory tract infections with excessive mucus: assists in thinning secretions, making them easier to clear and reducing infection‑related discomfort.

Mucosolvan may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Taste disturbance - Abdominal discomfort - Headache

Serious or Rare Side Effects: - Allergic reactions such as rash or angioedema - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Hepatic enzyme elevation or liver injury

When prescribing Mucosolvan, consider the following precautions to ensure safe use.

Renal impairment: assess kidney function and adjust therapy if necessary. Hepatic disease: monitor liver enzymes during treatment. Asthma: use with caution as bronchospasm may occur. Pregnancy: safety not established; discuss risks with a healthcare professional. Store at ambient temperature: keep in the original packaging, protect from moisture and heat.

Mucosolvan can interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Anticholinergic agents: may diminish the mucolytic effect of ambroxol. - Cytotoxic chemotherapy: increased risk of pulmonary toxicity when combined.

Moderate Interactions (Monitor Closely): - Bronchodilators: additive cough suppression may require dose adjustment. - Antihistamines: may mask cough, obscuring therapeutic response. - Oral contraceptives: possible alteration of metabolic clearance of ambroxol.